BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Plandai Biotechnology, Inc. (PLPL.OB) Launches New Investor-Friendly Website


3/19/2012 9:12:46 AM

SEATTLE, WA--(Marketwire - March 19, 2012) - Plandaí Biotechnology, Inc. (OTCBB: PLPL), a producer of highly bioavailable plant extracts, today announced the launch of a new, investor friendly website designed to educate the public about the company's proprietary CRS processing system and the importance of bioavailability in nutrition.

The website is easy to navigate and provides investors with quick access to historical SEC filings and press releases. The website also has several excellent photos of the Senteeko tea estate located in South Africa, along with discussions on the nature of tea production, ongoing research, and the importance of bioavailability. Company contact information and newsletter sign up is also provided.

The benefits of delivering high concentrate bioavailable phytonutrients allow the body to more efficiently absorb the active and stable nutrients and antioxidants. For example, green tea, which is rich in antioxidants critical for protecting white and red blood cells and boosting the body's immune system, is not readily absorbed in its natural state. According to published research, the average person needs to consume 8-10 cups of green tea in order to receive a clinical dose of the necessary gallate catechins. Plandaí's CRS hydrodynamic process is able to alter the isomeric properties of plant material so that they are more in line with that found in human tissues, thus increasing the absorbability by up to eight times that of other extracts.

Roger Duffield, Chief Executive Officer of Plandaí, commented, "As a management team, we value the importance of educating the public about bioavailability. Billions of dollars are spent annually on supplements and vitamin-enhanced products, but these are wasted dollars if what is being consumed is not in a form that the body can absorb and process. Our new website will be a useful tool for getting timely information to shareholders and concerned consumers while also providing updates as new research is completed and we draw nearer to full production."

About Plandai Biotechnology, Inc.

Plandaí Biotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principal holdings consist of land, farms and infrastructure in South Africa.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.


Contact:

Plandai Biotechnology, Inc.
Tel: (425) 466-0212
Email: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES